JAMA Clinical Reviews Treatment of Small Cell Lung Cancer
18 snips
Mar 31, 2025 Anne C. Chiang, an associate professor of medical oncology at Yale University, shares her expertise on small cell lung cancer (SCLC). She discusses the alarming prevalence tied to smoking and symptoms that can lead to misdiagnosis. Chiang highlights recent advancements, including immunotherapy from the Adriatic trial, which shows promise for limited-stage SCLC. Additionally, she emphasizes the vital role of palliative care and clinical trials, advocating for tailored treatments that improve outcomes for patients facing this challenging disease.
AI Snips
Chapters
Transcript
Episode notes
SCLC Incidence and Risk Factors
- Small cell lung cancer (SCLC) is rare, affecting 4.7 per 100,000 in the US in 2021.
- Smoking is the primary risk factor, with 95% of patients having a history.
SCLC Presentation
- SCLC patients often present with cough, shortness of breath, or hemoptysis.
- These symptoms can persist for months, sometimes misdiagnosed as a respiratory infection.
Asymptomatic SCLC
- Approximately 60% of SCLC patients are asymptomatic at presentation.
- Incidentalomas are often discovered through scans performed for unrelated reasons.